What is Entelos?
Entelos operates at the intersection of computational biology and clinical research, providing a sophisticated platform that simulates the system biology of virtual human patients. By leveraging advanced predictive modeling, the company enables drug development teams to identify biomarkers with greater precision and optimize patient-trial pairing. Their expertise spans complex disease modeling, including type II diabetes and cardiovascular conditions, offering a critical service that enhances the predictive accuracy of clinical outcomes. Through expert consulting and mechanism-based mathematical frameworks, Entelos serves as a vital partner for organizations seeking to streamline trial design and improve overall patient stratification in an increasingly complex regulatory environment.
How much funding has Entelos raised?
Entelos has raised a total of $39.6M across 2 funding rounds:
Series B
$14.6M
Series C
$25M
Series B (2000): $14.6M with participation from CRV, Abingworth, Brentwood Associates, and Boulder Ventures
Series C (2012): $25M, investors not publicly disclosed
Key Investors in Entelos
CRV
CRV is a venture capital firm that invests in early-stage tech startups, providing long-term partnership from founding to IPO.
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that transforms cutting-edge science into novel medicines through clinical co-development.
Brentwood Associates
Brentwood Associates is a growth-oriented private equity firm that partners with leadership teams to enhance essential services and drive category leadership.
What's next for Entelos?
With the support of its recent capital infusion, Entelos is well-positioned to scale its predictive modeling capabilities and expand its footprint in the global drug development market. The company's strategic roadmap likely involves deepening its disease modeling library and enhancing the computational throughput of its virtual patient platform. As the pharmaceutical industry continues to prioritize data-driven decision-making to reduce the high costs of clinical failures, Entelos's role as a facilitator of efficient trial design becomes increasingly central. Future growth will likely focus on integrating real-world evidence into their existing simulation models, thereby providing a more holistic view of patient responses and further cementing their status as an essential enterprise-level partner in the life sciences ecosystem.
See full Entelos company page
